Kevin Eggan

Founder at Q-State Biosciences

Kevin Eggan has extensive work experience in the field of bioscience and research. Kevin is currently the CSO/Head of Research and Early Development at BioMarin Pharmaceutical Inc. since October 2020. Prior to that, they founded EnClear Therapies in May 2018, QurAlis in January 2017, and Q-State Biosciences in June 2013.

Earlier in their career, Eggan held various positions at Harvard University. Kevin was a Professor from July 2012 until January 2022, an Associate Professor from July 2009 to June 2012, an Assistant Professor from July 2005 to June 2009, and a Harvard Junior Fellow from July 2003 to June 2005. During their time at Harvard, they also served as a Principal Investigator at the Harvard Stem Cell Institute from July 2004 until January 2022.

In addition to their academic and entrepreneurial roles, Eggan was a SAB member at Ipierian from January 2009 to January 2014.

Overall, Eggan's work experience demonstrates their expertise in the field of bioscience, as well as their entrepreneurial spirit and dedication to research and development.

Kevin Eggan completed their Bachelor of Science in Microbiology and Immunology at the University of Illinois Urbana-Champaign, from 1992 to 1996. Kevin then pursued a PhD in Biology at the Massachusetts Institute of Technology, from 1998 to 2003.

Links

Timeline

  • Founder

    June, 2013 - present

View in org chart